Listed

Aprea Therapeutics, Inc.

APRENasdaqCIK 1781983HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.0m, Q2 FY2026
Net income−$3.6m, Q2 FY2026
Aprea Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$k(3,523)Operating income, Q3 FY2023, three months to 2023-09-30−$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure(3,675)Operating income, Q4 FY2023, three months to 2023-12-31−$3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-25, accession 0001558370-25-003588. Derived: 12-month figure less the 9-month figure.Report this figure(3,150)Operating income, Q1 FY2024, three months to 2024-03-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure(3,847)Operating income, Q2 FY2024, three months to 2024-06-30−$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure(4,097)Operating income, Q3 FY2024, three months to 2024-09-30−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure(3,226)Operating income, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure(4,086)Operating income, Q1 FY2025, three months to 2025-03-31−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(3,388)Operating income, Q2 FY2025, three months to 2025-06-30−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure(3,117)Operating income, Q3 FY2025, three months to 2025-09-30−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure(2,643)Operating income, Q4 FY2025, three months to 2025-12-31−$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure(3,430)Operating income, Q1 FY2026, three months to 2026-03-31−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(4,032)Operating income, Q2 FY2026, three months to 2026-06-30−$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Income tax$k0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-25, accession 0001558370-25-003588. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Net income$k(3,205)Net income, Q3 FY2023, three months to 2023-09-30−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure(3,443)Net income, Q4 FY2023, three months to 2023-12-31−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-25, accession 0001558370-25-003588. Derived: 12-month figure less the 9-month figure.Report this figure(2,810)Net income, Q1 FY2024, three months to 2024-03-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure(3,470)Net income, Q2 FY2024, three months to 2024-06-30−$3.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure(3,784)Net income, Q3 FY2024, three months to 2024-09-30−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure(2,895)Net income, Q4 FY2024, three months to 2024-12-31−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure(3,933)Net income, Q1 FY2025, three months to 2025-03-31−$3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure(3,239)Net income, Q2 FY2025, three months to 2025-06-30−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure(2,972)Net income, Q3 FY2025, three months to 2025-09-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure(2,456)Net income, Q4 FY2025, three months to 2025-12-31−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure(3,288)Net income, Q1 FY2026, three months to 2026-03-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure(3,591)Net income, Q2 FY2026, three months to 2026-06-30−$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Diluted EPS$ per share(0.86)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figurenot reported(0.67)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure(0.58)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure(0.64)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figurenot reported(0.66)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(0.53)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure(0.47)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figurenot reported(0.22)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Basic EPS$ per share(0.86)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.86 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figurenot reported(0.67)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure(0.58)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure(0.64)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figurenot reported(0.66)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(0.53)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure(0.47)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figurenot reported(0.22)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(0.07)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure

Balance sheet

Cash and equivalents$41.2m, Q2 FY2026
Shareholders' equity$38.5m, Q2 FY2026
Aprea Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m25.4Cash and equivalents, Q3 FY2023, at 2023-09-30$25.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure21.6Cash and equivalents, FY2023, at 2023-12-31$21.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-25, accession 0001558370-25-003588.Report this figure32.4Cash and equivalents, Q1 FY2024, at 2024-03-31$32.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure28.7Cash and equivalents, Q2 FY2024, at 2024-06-30$28.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure26.2Cash and equivalents, Q3 FY2024, at 2024-09-30$26.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure22.8Cash and equivalents, FY2024, at 2024-12-31$22.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-16, accession 0001104659-26-028068.Report this figure19.3Cash and equivalents, Q1 FY2025, at 2025-03-31$19.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure16.5Cash and equivalents, Q2 FY2025, at 2025-06-30$16.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure13.7Cash and equivalents, Q3 FY2025, at 2025-09-30$13.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure14.6Cash and equivalents, FY2025, at 2025-12-31$14.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure46.5Cash and equivalents, Q1 FY2026, at 2026-03-31$46.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure41.2Cash and equivalents, Q2 FY2026, at 2026-06-30$41.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Current assets$m25.6Current assets, Q3 FY2023, at 2023-09-30$25.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001558370-23-018572.Report this figure22.5Current assets, FY2023, at 2023-12-31$22.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-25, accession 0001558370-25-003588.Report this figure33.1Current assets, Q1 FY2024, at 2024-03-31$33.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001558370-24-008069.Report this figure29.6Current assets, Q2 FY2024, at 2024-06-30$29.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011806.Report this figure26.5Current assets, Q3 FY2024, at 2024-09-30$26.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure23.6Current assets, FY2024, at 2024-12-31$23.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-16, accession 0001104659-26-028068.Report this figure19.8Current assets, Q1 FY2025, at 2025-03-31$19.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure16.9Current assets, Q2 FY2025, at 2025-06-30$16.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure13.9Current assets, Q3 FY2025, at 2025-09-30$13.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure15.6Current assets, FY2025, at 2025-12-31$15.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure47.2Current assets, Q1 FY2026, at 2026-03-31$47.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure41.9Current assets, Q2 FY2026, at 2026-06-30$41.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Total assets$m25.8Total assets, Q3 FY2023, at 2023-09-30$25.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001558370-23-018572.Report this figure22.7Total assets, FY2023, at 2023-12-31$22.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-25, accession 0001558370-25-003588.Report this figure33.2Total assets, Q1 FY2024, at 2024-03-31$33.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001558370-24-008069.Report this figure30.0Total assets, Q2 FY2024, at 2024-06-30$30.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0001558370-24-011806.Report this figure26.9Total assets, Q3 FY2024, at 2024-09-30$26.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure24.0Total assets, FY2024, at 2024-12-31$24.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-16, accession 0001104659-26-028068.Report this figure20.2Total assets, Q1 FY2025, at 2025-03-31$20.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure17.3Total assets, Q2 FY2025, at 2025-06-30$17.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure14.3Total assets, Q3 FY2025, at 2025-09-30$14.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure15.9Total assets, FY2025, at 2025-12-31$15.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure47.6Total assets, Q1 FY2026, at 2026-03-31$47.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure42.3Total assets, Q2 FY2026, at 2026-06-30$42.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Current liabilities$m4.2Current liabilities, Q3 FY2023, at 2023-09-30$4.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001558370-23-018572.Report this figure4.4Current liabilities, FY2023, at 2023-12-31$4.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-25, accession 0001558370-25-003588.Report this figure3.0Current liabilities, Q1 FY2024, at 2024-03-31$3.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001558370-24-008069.Report this figure3.1Current liabilities, Q2 FY2024, at 2024-06-30$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011806.Report this figure3.6Current liabilities, Q3 FY2024, at 2024-09-30$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure3.4Current liabilities, FY2024, at 2024-12-31$3.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-16, accession 0001104659-26-028068.Report this figure3.4Current liabilities, Q1 FY2025, at 2025-03-31$3.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure3.2Current liabilities, Q2 FY2025, at 2025-06-30$3.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure2.7Current liabilities, Q3 FY2025, at 2025-09-30$2.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure2.8Current liabilities, FY2025, at 2025-12-31$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure5.3Current liabilities, Q1 FY2026, at 2026-03-31$5.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure3.1Current liabilities, Q2 FY2026, at 2026-06-30$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure
Total liabilities$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m20.3Shareholders' equity, Q3 FY2023, at 2023-09-30$20.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure17.0Shareholders' equity, FY2023, at 2023-12-31$17.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-16, accession 0001104659-26-028068.Report this figure28.9Shareholders' equity, Q1 FY2024, at 2024-03-31$28.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure25.6Shareholders' equity, Q2 FY2024, at 2024-06-30$25.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure21.9Shareholders' equity, Q3 FY2024, at 2024-09-30$21.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure19.3Shareholders' equity, FY2024, at 2024-12-31$19.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure15.5Shareholders' equity, Q1 FY2025, at 2025-03-31$15.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure13.4Shareholders' equity, Q2 FY2025, at 2025-06-30$13.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure10.9Shareholders' equity, Q3 FY2025, at 2025-09-30$10.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure12.4Shareholders' equity, FY2025, at 2025-12-31$12.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure41.6Shareholders' equity, Q1 FY2026, at 2026-03-31$41.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure38.5Shareholders' equity, Q2 FY2026, at 2026-06-30$38.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure

Cash flow

Operating cash flow−$3.3m, Q2 FY2026
Capital expenditure$0, Q4 FY2024
Aprea Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(2,242)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001558370-24-014767. Derived: 9-month figure less the 6-month figure.Report this figure(3,740)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-25, accession 0001558370-25-003588. Derived: 12-month figure less the 9-month figure.Report this figure(3,936)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure(3,642)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001558370-25-011152. Derived: 6-month figure less the 3-month figure.Report this figure(2,468)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001104659-25-109867. Derived: 9-month figure less the 6-month figure.Report this figure(3,511)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure(3,631)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(3,131)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001104659-26-094544. Derived: 6-month figure less the 3-month figure.Report this figure(3,171)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001104659-25-109867. Derived: 9-month figure less the 6-month figure.Report this figure(2,961)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figure(2,757)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure(3,279)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001104659-26-094544. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reported7.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$7.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-25, accession 0001558370-25-003588. Derived: 12-month figure less the 9-month figure.Report this figure8.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure7.5Capital expenditure, Q2 FY2024, three months to 2024-06-30$7.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0001558370-25-011152. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001104659-25-109867. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001104659-26-028068. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)53.48m, Q2 FY2026
Aprea Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares1.7Diluted shares (weighted), Q3 FY2022, three months to 2022-09-301,732,783 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001558370-23-018572.Report this figure3.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-313,260,484 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001558370-24-008069.Report this figure3.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-303,731,571 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0001558370-24-011806.Report this figure3.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-303,735,176 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001558370-24-014767.Report this figure4.2Diluted shares (weighted), Q1 FY2024, three months to 2024-03-314,198,326 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001558370-25-007667.Report this figure5.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-305,937,291 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001558370-25-011152.Report this figure5.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-305,939,755 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure6.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-315,993,866 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure6.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-306,083,329 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure6.4Diluted shares (weighted), Q3 FY2025, three months to 2025-09-306,372,938 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001104659-25-109867.Report this figure14.7Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3114,685,448 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001104659-26-059743.Report this figure53.5Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3053,483,504 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure

Shares outstanding: 12.59mShares outstanding, period not labelled, at 2026-08-1212,591,136 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-12, accession 0001104659-26-094544.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.